Key Findings
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), through its subsidiary Scinai Biopharma Services Ltd., has entered into a definitive agreement for development and clinical manufacturing valued at $5.1 million. This agreement significantly boosts the company’s CDMO business, bringing total committed customer orders to approximately $7.6 million, compared to $1.9 million at the end of 2025.
Technical Details and Timeline
The agreement supports a phased operational timeline with a U.S.-based, Nasdaq-listed biopharmaceutical partner:
- 2026: Focus on development activity.
- 2027: Planned clinical manufacturing.
Furthermore, the contract includes potential additional clinical manufacturing for the period from late 2027 through the first half of 2028. This potential extension carries an indicative, uncommitted service-fee value of $5.85 million. This figure excludes costs for initial manufacturing activities, qualification, and additional scale-up that have not yet been priced.
Background & Context
Scinai operates as a dual-model organization, maintaining an immunology-focused therapeutic development platform while simultaneously growing its contract development and manufacturing organization (CDMO) services via Scinai Biopharma Services Ltd.
Significance & Outlook
The 300% increase in committed customer orders indicates a rapid expansion of Scinai’s CDMO footprint. By securing a definitive agreement with a Nasdaq-listed partner, the company establishes a clear revenue and operational roadmap extending into the first half of 2028, provided the uncommitted service-fee portions are realized.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
